Page 42 - David Ricks News Today

(NEW YORK) -- Eli Lilly will cut the price of its most commonly prescribed insulin products by 70% and expand a program that caps patient costs at $35 per month, the company said on Wednesday. "While the current healthcare system provides access to insulin for most people with diabetes, it still does not provide affordable

Eli Lilly will cut prices for some older insulins later this year and immediately expand a cap on costs insured patients pay to fill prescriptions.

Eli Lilly will cut prices for some older insulins later this year and immediately expand a cap on costs insured patients pay to fill prescriptions.

“The aggressive price cuts we’re announcing today should make a real difference for Americans with diabetes," said Lilly's Chair and CEO David Ricks.

Eli Lilly & Company announced cost reductions of up to 70% of its most commonly prescribed insulins today, saying it is committed to making sure its life-saving drugs are “safe, reliable and affordable” to people who rely on them. 

Eli Lilly will cut prices for some older insulins later this year and immediately expand a cap on costs insured patients pay to fill prescriptions.

“The aggressive price cuts we’re announcing today should make a real difference for Americans with diabetes," said Lilly's Chair and CEO David Ricks.

Eli Lilly will cut prices for some older insulins later this year and immediately expand a cap on costs insured patients pay to fill prescriptions.

“The aggressive price cuts we’re announcing today should make a real difference for Americans with diabetes," said Lilly's Chair and CEO David Ricks.

“The aggressive price cuts we’re announcing today should make a real difference for Americans with diabetes," said Lilly's Chair and CEO David Ricks.